Mini-review

Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis

Kwun Wah Wen, Blossom Damania *

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA

A R T I C L E   I N F O

Article history:
Received 22 December 2008
Received in revised form 10 July 2009
Accepted 13 July 2009
Available online xxxx

Keywords:
KSHV
Oncogenesis
AIDS-related malignancies
Viral latency
Lytic replication

A B S T R A C T

Kaposi sarcoma-associated herpesvirus (KSHV) is a double-stranded DNA herpesvirus belonging to the γ-herpesvirinae subfamily. KSHV has been associated with the development of three neoplastic diseases: Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). In this review, we discuss the three KSHV-associated malignancies, KSHV genome, latent and lytic aspects of the viral lifecycle, putative viral oncogenes, as well as therapeutic regimens used for the treatment of KS, PEL, and MCD.

© 2009 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

The members of the herpesviridae family are well represented in nature and can be found in many different species across the animal kingdom. They are also highly adapted to their hosts and are thought to have coevolved with their hosts for millions of years. Typically, herpesviruses have a double-stranded DNA genome (124–230 kb) enclosed in an icosahedral capsid (~125 nm in diameter) composed of 162 capsomeres. The capsid structure is surrounded by an amorphous tegument layer that separates it from the outer, glycoprotein-decorated, envelope. Common to all human herpesviruses is their ability to adapt very well to the cellular milieu of the infected host and their ability to evade host immune responses to establish life-long latent infection. Based on their biological properties including host range, replication cycle and cell tropism, these viruses are classified into the α-, β-, and γ-herpesvirinae subfamilies [1].

There are eight known human herpesviruses (HHV). Most of the human population is infected with one or more of these viruses, and they rarely cause severe disease in the host unless the host immune system is compromised. Human herpesviruses belonging to the α subfamily include herpes simplex viruses (HSV) 1 and 2 (HHV-1 and HHV-2), and varicella-zoster virus (VZV; HHV-3). Members of the human β-herpesvirinae include cytomegalovirus (CMV; HHV-5), HHV-6 variants A and B, and HHV-7. Human γ-herpesvirinae include Epstein–Barr virus (EBV; HHV-4) and Kaposi sarcoma-associated herpesvirus (KSHV; HHV-8). Strikingly the members of γ-herpesvirinae are strongly associated with neoplastic disease. For example, EBV is distinctly associated with Burkitt’s lymphoma, Hodgkin’s lymphoma, nasopharyngeal carcinoma, T and natural killer cells lymphoma, and post-transplant lymphoma [2–5]. KSHV is the etiological agent of several human cancers including Kaposi sarcoma (KS) [6,7], primary effusion lymphoma (PEL) [8], and the plasmablastic variant of multicentric Castleman disease (MCD) [9,10]. Additionally, there have also been reports of KSHV-associated solid lymphomas of HIV-positive and negative individuals [11] as well as KSHV-associated lymphomas in patients with...
primary immunodeficiencies such as common variable immunodeficiency [12].

The γ-herpesviruses have evolved to possess a plethora of viral gene products that intricately subvert normal cellular pathways. The dysregulated signaling pathways include those involved in cell cycle progression, apoptosis, immune surveillance, and antiviral responses. γ-herpesviruses are masters of altering these pathways in favor of their survival. They are known to establish persistent viral infection, and to evade viral clearance by actively suppressing apoptosis and escaping immune detection. The survival mechanisms used by these viruses are thought to inadvertently contribute to host cell transformation and the development of neoplasia, which is most frequently seen in the setting of immunodeficiency. In this review, we will focus on KSHV in terms of its associated clinical diseases and current therapies, as well as viral genes implicated in tumorigenesis and oncogenesis.

2. Clinical diseases associated with KSHV infection

2.1. Kaposi sarcoma

Kaposi sarcoma was named by Dr. Moritz Kaposi, a prominent Hungarian dermatologist, who first described the rare classical form of KS as “idiopathic multiple pigmented sarcoma of the skin” in 1872 [13]. Since the 1950s, an infectious agent was suspected to cause KS. The discovery of the causative agent of KS, however, was not intensively pursued until the early 1980s, when the incidence of KS dramatically increased in homosexual and bisexual HIV-positive individuals during the AIDS epidemic. The sudden surge of KS incidence among HIV-infected individuals strongly suggested an infectious agent and epidemic. The incidence of KS concurrently peaked with HIV diagnoses. Due to its strong association with AIDS, KS was identified as an AIDS-defining illness and served as a marker for HIV disease in the mid-1980s [25]. Indeed, KS is the most common malignancy associated with HIV infection and can lead to significant mortality [26]. KS is the most common tumor in African men [27–29]. This epidemiologic form of KS is found with increased frequency in homosexual AIDS patients who are relatively young. With the advent of highly active antiretroviral therapy (HAART) in the 1990s, the incidence and mortality of AIDS-associated KS have dramatically dropped [30,31]. However, KS continues to remain the most common AIDS-associated cancer in developed nations and in developing countries [32].

Another form of KS, known as iatrogenic/post–transplant KS, is associated with immune suppression after long-term immunosuppressive therapy used to prevent rejection of solid allografts [33]. Renal transplant patients are the most likely group to develop this form of KS. Interestingly, the KSHV-infected endothelial cells or lymphocytes found in KS lesions in these patients can originate from donor tissues [34]. Reduction or withdrawal of immunosuppressive therapy has been shown to be effective in resolving iatrogenic KS. However, this also increases the likelihood of allograft rejection.

2.2. Primary effusion lymphoma

In addition to KS, primary effusion lymphoma (PEL), sometimes referred to as body cavity-based lymphoma (BCBL), has been strongly associated with KSHV [8]. PEL is a unique form of NHL found more commonly in immunocompromised AIDS patients. Unlike KS, PEL is derived from clonally expanded malignant B cells and presents as a lymphomatous effusion tumor contained in various body cavities such as the pericardium, pleura, and peritoneum. There are, however, reports of PEL as a solid mass in lymph nodes and other organs [35]. PEL is aggressive and rapidly progressing, and can cause high fatality. The mean survival time for patients with PEL is approximately 2–6 months [36]. Histologically, PEL cells are larger than normal lymphocytes and erythrocytes, and contain features of both large cell immunoblastic lymphoma and anaplastic large cell lymphoma. PEL cells express CD45, activation-associated antigens, clonal immunoglobulin rearrangements but usually lack B cell–associated antigens [37]. PEL cells can be KSHV single-positive or KSHV/EBV
double-positive. KSHV genomes are found in PEL cells at a high copy number (50–150 viral genomes per infected cell) [8,38,39].

2.3. Multicentric Castleman disease

The plasmablastic variant of multicentric Castleman disease (MCD) is also highly associated with KSHV; however, the other form of MCD, namely, the hyaline variant of MCD, is not. MCD is a reactive lymphadenopathy that is considered non-neoplastic as polyclonal B-cell populations are usually found in the lesion. However, monoclonal B cell expansion has also been reported for plasmablastic MCD [40,41]. Plasmablastic MCD can have an aggressive and rapid progression leading to high fatality. Histologically, germinal center expansion and vascular endothelial proliferation occur within the involved lymph nodes of MCD. Dysregulated IL-6 levels, likely contributed in part by virally encoded IL-6 (vIL-6) [42], may account for the clinico-pathophysiology of MCD. Like KS and PEL, KSHV genomes are detectable in almost all HIV-positive MCD cases and about 50% of HIV-negative MCD cases. [10,16]. Additionally, KSHV has been shown to be associated with a plasmablastic variant of MCD.

3. The KSHV genome

KSHV has a double-stranded DNA genome and its size ranges from 165 to 170 kb [43,44]. The long unique region (LUR), which is about 138 to 140.5 kb in length and contains all of the KSHV ORFs, is flanked by terminal repeat (TR) sequences at both ends of the linear viral genome. Each TR is 801 bp in length and is highly GC-rich. The number of TRs varies among KSHV isolates, ranging from 16 to 75 [45], which accounts for the variation in the genome sizes of KSHV isolates. The KSHV genome exhibits very high degree of similarity to retroperitoneal fibromatosis-associated herpesvirus (RFHV) and rhesus monkey rhadinovirus (RRV) in the rhadinovirus subfamily of γ-herpesvirinae. RFHV appears to be more closely related to KSHV. Although many of the KSHV ORFs are conserved in α- and β-herpesviruses, the virus does contain a significant number of unique ORFs not found in other herpesviruses (Table 2). These KSHV-specific ORFs are designated K1 to K15, based on their relative locations (from left to right) in the KSHV genome (Fig. 1). Moreover, KSHV also contains several viral genes that have been pirated from the host genome and are homologues of cellular genes [46].

Many viral genes are involved in signal transduction (e.g. K1 and K15), cell cycle regulation (e.g. vCyclin and LANA-1), inhibition of programmed cell death (e.g. K1, vFLIP, and vBcl-2) and immune modulation (e.g. viral chemokine receptors, vIRFs, K3, and K5). Additionally, a number of KSHV genes are expressed by alternative splicing (reviewed in [47]), by the use of alternative transcriptional start sites, or internal ribosome entry sites (IRES) [48,49]. Very recently, a total of 12 microRNAs have been discovered in the KSHV genome [50–53]. Ten of these microRNAs were found in the non-coding region between K12/Kaposin and K13/Orf71/vFLIP, and two were located within the K12 ORF (Fig. 1). All of the KSHV microRNAs were expressed during latency [50,54–56], with a sub-set of these microRNAs being upregulated during the lytic cycle. Recent evidence has identified cellular and viral targets of these microRNAs, as well as their roles in KSHV pathogenesis.
Besides microRNAs, KSHV also produces a non-coding RNA transcript that is 1077 bp in size, poly-adenylated and exclusively nuclear (PAN) [60–63]. PAN RNA is made during the lytic cycle and has been shown to retain intronless RNA in the nucleus and block the assembly of an export-competent mRNP.

4. The viral lifecycle

Like other herpesviruses, KSHV displays two different phases of its viral lifecycle. Latent KSHV is characterized by a circularized, extra-chromosomal viral genome (epi- some) and the expression of a very small subset of latent transcripts in the infected cells; no functional or infectious viral particles are produced during latency. In latently infected cells, in all three KSHV-associated malignancies, the expression of OrfK12/Kaposin, K13/Orf71/vFLIP, Orf72/vCyclin, and Orf73/LANA has been detected. In PEL and MCD cells, OrfK10.5/LANA-2/vIRF3 expression was also detected [64]. The lytic cycle is characterized by the replication of linear viral genomes, and the expression of more than 80 transcripts in a highly orchestrated temporal order of immediate-early (α), early (β), and late (γ) categories. These categories are defined by sensitivity to cycloheximide and phosphonoacetic acid (PAA) treatment after chemical induction of viral reactivation [65–68]. Unlike early and late genes, immediately-early (IE) genes are not sensitive to the protein synthesis inhibitor cycloheximide, as the expression of IE genes does not rely on viral protein synthesis. IE genes are important for regulating the subsequent transcriptional cascade. KSHV-encoded Rta is an IE lytic master switch protein that has been shown to be required and sufficient for initiating the lytic replication cycle to completion. The IE gene K8/K-bZIP appears to antagonize Rta transactivation activity [69,70]. The third IE gene, Orf45, is important for the suppression of interferon induction by lytic viral infection or reactivation [71]. In contrast to IE genes, early and late genes are not sensitive to cycloheximide, and are distinguished by their dependence on DNA replication. The expression of early genes is independent of viral DNA synthesis and is not inhibited by PAA treatment, whereas the expression of late genes is dependent on the replication of viral genomes and therefore, sensitive to PAA inhibition. To model KSHV lytic replication in vitro, chemical induction using n-butylate and 12-O-tetradecanoylphorbol-13-acetate (TPA) to reactivate PEL cells has been reported. TPA treatment can lead to reactivation in about 20–30% of PEL cells [43,72]. The general function of early and late genes is to facilitate the replication of viral genomes, viral assembly and egress.

5. Putative viral genes involved in KSHV transformation and oncogenesis

Transformation is a key event in the multistep process of oncogenesis. It involves changes in cellular signaling pathways and cell morphology, leading to a state of uncontrolled proliferation. In KSHV, transformation of endothelial cells can lead to chromosome instability [73], alteration of cellular gene expression profiles [74], acquisition of telomerase activity and anchorage-independent growth [75], increase in cell invasiveness [76] as well as long-term proliferation and survival of these cells [75,77]. A number of KSHV-encoded proteins are believed to have transforming and oncogenic properties. They include both latent and lytic proteins: the latent proteins are likely to enhance the survival and proliferation of the infected cells, whereas the lytic viral proteins are believed to mediate paracrine secretion of growth and angiogenic factors essential for tumor growth and development. This is postu- lated based partially on the observation that the latent genes (especially those encoded on the latency-associated cassettes) are detectable in situ in the majority of KS, PEL, and MCD samples, whereas the lytic genes (e.g. K1, vIL-6, and vGPCR) are detectable in only small sub-sets of tumor samples. These oncogenic viral products are described below.

5.1. LANA

In addition to its role in the establishment and maintenance of latency [78–80], the latency-associated nuclear antigen (LANA) can perturb a plethora of cellular pathways to contribute to tumorigenesis. For example, LANA can physically associate with p53 and inhibit p53-mediated transcription activity and apoptosis [81]. LANA can also inactivate the tumor suppressor retinoblas- toma (Rb) gene and release E2F transactivator which induces cell to transit through the G1/S cell cycle checkpoint [82]. To promote G1/S transition, LANA interacts with the bromodomomain-containing protein RING3/Brd2 [83–86], and can sequester glycogen synthase kinase (GSK)-3β in the nucleus, which prevents GSK-3β from complexing with, and degrading, β-catenin in the cytoplasm. The stabilized β-catenin can translocate into the nucleus, where it complexes with the transcription factors lymphoid enhancing factor (LEF) and T-cell factor (TCF) to transactivate responsive genes including CCND1 and Myc, which have been implicated in cell cycle regulation and oncogenesis [87,88]. LANA can cooperate with the oncogene H-Ras to transform primary rat embryo fibroblasts and render them tumorigenic [82]. LANA was also shown to upregulate human telomerase reverse transcriptase (hTERT) gene expression and to immortalize primary HUVEC and increase their proliferation [89]. Finally, transgenic mice expressing LANA under the endogenous LANA promoter developed splenic follicular hyperplasia with increased germinal centers as well as lymphomas [90]. Based on these findings, LANA appears to at least set the initial stage for sarcomagenesis and lymphomagenesis.

5.2. K13/vFLIP

The viral FLICE (Fas-associated death-domain like IL-1 β-converter enzyme) inhibitory protein (vFLIP) is also known as K13, and is encoded by Orf71 [66,67,91]. Latent expression of vFLIP occurs via splicing of the LANA trans- script from the tricistronic messenger RNA, and via the use of the IRES in vCyclin coding sequences [49,92,93]. Similar to cellular FLIPs, vFLIP inhibits death receptor sig-
naling by specifically abrogating the interaction between Fas-associated death-domain (FADD) and caspase-8 [94]. The inhibition of this pathway blocks Fas-mediated apoptosis, thus providing a survival advantage for KSHV-infected cells [95]. In addition to blocking the extrinsic apoptotic pathway, vFLIP also associates with the IKK complex and the heat shock protein 90 (hsp90) to induce NFκB survival signaling [96–99]. The induced NFκB signaling is significant in at least two aspects: viral latency and oncogenesis. First, NFκB activation by vFLIP is critical for vFLIP inhibition of lytic replication via the AP-1 pathway [100,101]. Second, the enhanced NFκB signaling may be important for the transforming and oncogenic potential of vFLIP as demonstrated in Rat-1 fibroblast assays and tumors in nude mice [102]. In primary dermal microvascular endothelial cells, vFLIP expression was shown to induce anoinis (detachment induced apoptosis), but not apoptosis, due to growth factor depletion suggestive of its role in paracrine factor secretion and KS development [103].

5.3. Kaposin

The Kaposin transcripts represent the most abundantly expressed viral transcripts during KSHV latency. Kaposin A is encoded by OrfK12, while Kaposins B and C initiate upstream of OrfK12 at two repeat regions (termed DR1 and DR2), and their transcripts extend into OrfK12 [104]. Kaposin A has oncogenic potential as demonstrated by focus formation assay in transfected Rat-3 cells. This morphological change is mediated through interaction with cytohesin-1 [105]. Cytohesin-1 is a guanine nucleotide exchange factor for the GTPase ARF as well a regulator of cell adhesion. When injected into athymic mice, the transformed Rat-3 cell lines containing Kaposin sequences produced high-grade, highly vascular, undifferentiated sarcomas [106]. In contrast to the undetectable protein level of Kaposin A in virus-infected cells, Kaposin B was shown to be the most abundant Kaposin protein in the PEL cell line BCBL-1 [104]. Kaposin B functions to stabilize cytokine expression such as IL-6 and GM-CSF by inhibiting degradation of their messages. The inhibition was achieved via Kaposin B binding and activation of MK2 kinase, which inhibits degradation of mRNA containing AU-rich elements (e.g. cytokines) [107]. The mRNA stabilization activity is dependent on the direct repeat (DR1 and DR2) elements of Kaposin B [108].

5.4. K1

K1 is a 46-kDa type I membrane glycoprotein encoded by the first open reading frame [109]. K1 is also designated VIP (variable ITAM-containing protein) as it contains an immunoreceptor tyrosine-based activation motif (ITAM) [110]. K1 demonstrates early lytic kinetics and its expression has been detected in KS, PEL, and MCD [67,109,111,112]. K1 has been shown to transform Rat-1 rodent fibroblasts by inducing morphological changes and foci formation [113], and can functionally substitute for STP in the context of HVS infection to immortalize T lymphocytes to IL-2-independent growth as well as induce lymphomas [113]. Transgenic mice expressing the K1 gene showed constitutive activation of NFκB and Oct-2, increased Lyn tyrosine kinase phosphorylation and activity, as well as increased basic fibroblast growth factor (bFGF) expression [114]. Some of these mice developed tumors with features resembling the spindle-cell sarcomatoid tumor and malignant plasmablastic lymphoma [114].

Structurally, K1 contains a long N-terminal extracellular domain, a transmembrane domain, and a short C-terminal cytoplasmic tail. The C-terminus of K1 is well conserved and contains an ITAM that is normally important for lymphocyte activation signaling [110]. K1 appears to be constitutively active and independent of ligand binding [113]. In B cells, K1 has been shown to activate PI3 K (p85 subunit), Akt, Vav, and Syk kinases, and to induce NFAT and NFκB transcriptional activities for cell survival [110,115,116]. In addition, K1 can prevent death receptor-mediated apoptosis of B lymphocytes by inhibiting the induction of FasL expression and activating the PI3 K/Akt pathway [115]. Another striking feature of K1 is the induced downregulation of surface B cell receptor by endoplasmic reticular sequestration [117]. This may inhibit apoptosis as a consequence of BCR signaling. K1 signaling activity in B cells has been linked to K1 internalization and since K1 also co-internalizes with BCR, it suggests a possible mechanism of BCR downregulation from the cell surface [118]. In epithelial and endothelial cells, K1 expression induced the secretion of angiogenic factors, including vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 [119]. K1 also activated the PI3 K/Akt/mTOR pathway in endothelial cells [111]. In endothelial cells, K1 has been shown to immortalize and extend the life span of primary human umbilical vein endothelial cells (HUVEC) in culture [111]. K1 ITAM expression also activates both the VEGF/VEGFR-2 and the PI3 K/Akt signaling pathways in HUVEC [111]. Cumulatively, these data suggest a paracrine model in which K1-mediated secretion of cytokines is involved in the development of KSHV-associated diseases [119]. Thus K1 appears to be important in KSHV-associated tumorigenesis and angiogenesis.

5.5. vGPCR

Viral G-protein–coupled receptor is encoded by Orf74 of KSHV [120,121]. It is expressed early during the lytic cycle and is a viral homologue of the cellular angiogenic IL-8 receptor [122]. vGPCR possesses seven transmembrane domains that are universally found in cellular GPCRs [122]. The expression of vGPCR can be found in only a small fraction of KS, PEL, and MCD samples [123]. This protein has potent oncogenic activities, as evidenced by its ability to transform and form foci in murine NIH3T3 cells as well as to produce tumors when injected into nude mice [124]. Like K1, vGPCR can immortalize HUVEC and protect these cells from apoptosis induced by serum starvation [125,126]. A sub-set of vGPCR transgenic mice developed KS-like angioproliferative lesions with surface markers and cytokine profiles resembling those of KS [127–129]. As observed in KSHV-associated malignancies, the expression of vGPCR was detected in only a small population of cells in the transgenic tumors and in a few other tissues,
suggesting that vGPCR-mediated tumor formation is driven by spontaneous lytic reactivation in the background of latently infected cells. VEGF secretion was increased in these vGPCR-induced tumors [127]. Unlike its cellular homologues, vGPCR signaling is constitutive and independent of ligand binding [130]. vGPCR can activate mitogen-activated protein kinases (MAPKs) [123], PLC [126], PI3 K [126], and Akt [125] in endothelial cells. These data implicate that like KSHV K1, autocrine/paracrine signaling of vGPCR might contribute to KSHV-associated oncogenesis and angiogenesis.

5.6. vIL-6

Viral interleukin-6 encoded by OrfK2 is a homologue of cellular IL-6 (24.6% amino acid sequence identity) [46]. Viral IL-6 expression can be detected in KS, PEL, and MCD samples to different extents (MCD > PEL ∼ KS) [64,131]. Interestingly, IL-6 overexpression was suspected to be important in KS and MCD pathogenesis, prior to the discovery of KSHV [132,133]. Similar to cellular IL-6, vIL-6 signaling triggers the JAK/STAT (Janus tyrosine kinases signal transducers and activators of transcription) [134], MAPK, and H7-sensitive pathways [135]. The JAK/STAT pathway induced by vIL-6 results in increased VEGF expression and signaling in an autocrine/paracrine fashion [136]. Unlike its cellular IL-6 homologue, whose signaling depends upon both gp80 (IL-6Rα) and gp130, vIL-6 signaling can be achieved through gp130 alone [134]. Therefore, vIL-6 seems to bypass the normal cellular checkpoint of gp80 coupling with gp130 for IL6 binding. Innulation of NIH3T3 cells stably expressing vIL-6 into athymic mice resulted in tumor formation, hematopoiesis, and plasmacytosis compared to the control mice. The vIL-6-expressing tumors were also more vascularized, which correlated with an elevated level of VEGF secretion [137].

5.7. vIRF-1

The viral interferon regulatory factor-1 is encoded by KSHV OrfK9 [138,139]. In contrast to the other three KSHV-encoded IRFs, the vIRF-1 transcript is unspliced. In PEL cells, the expression of vIRF-1 is low during latency but can be induced to high levels during lytic infection [140]. The most apparent function of vIRF-1 is to suppress both type I and type II interferon responses [139,141,142]. vIRF-1 can compete with cellular IRF3 to interact with the transcriptional coactivator CBP and p300. This interferes with the formation of the IRF3/CBP/p300 complexes [141,143]. In addition to suppressing the host anti-viral response, vIRF-1 can block apoptosis induced by tumor necrosis factor α (TNFα) and p53, respectively [141,144]. Viral IRF-1 can physically associate with p53 and repress its transactivation and apoptotic functions through inhibition of p53 phosphorylation and acetylation [144,145]. Viral IRF-1 is a potential oncogene, as NIH3T3 cells stably expressing vIRF-1 can grow under conditions of serum deprivation. These cells exhibit loss of contact inhibition in soft agar and can form tumors in nude mice [142]. Transformation of vIRF-1 expressing NIH3T3 cells was found to be mediated by the induction of Myc proto-oncogene through vIRF-1 activation of the plasmacytoma repressor factor (PRF) element [146].

In addition to their transforming/oncogenic properties in overexpression systems (in isolation), most of the putative oncogenic KSHV gene products (e.g. LANA, vFLIP, vIL-6, Kapson B, K1, vGPCR, and vIRF-1) described in this section can be detected in KS, PEL, and MCD specimens, albeit with differential contribution (Table 1). This further corroborates their important roles in the initiation and/or maintenance of KSHV-associated malignancies. Very generally speaking, predominantly latent proteins are expressed in KS and PEL cells, but both latent and lytic proteins are expressed in MCD. Intriguingly, processivity factor-8 (PF-8)/Orf59 and vIRF-1 can be detected in PEL cell line but not in PEL primary tissues [64,147]. Furthermore, PEL cell lines require chemical induction to express vIL-6 while primary PEL tumor cells express vIL-6 without the dependence of lytic reactivation [64,131,148]. The discrepancies could be due to the loss of tumor microenvironment in cell lines or adaptation of PEL cells during passages. This may raise a potential problem of using PEL cell lines to extrapolate the PEL disease state.

Although we have not described the functions of all the unique genes encoded by KSHV due to space restrictions, a brief description of these genes is listed in Table 2.

6. Treatment of KS, PEL, and MCD

Treatment options for KS are based on disease severity, the KS subtype, and immune status. For relatively mild and limited KS, local treatment options such as topical alitretinoin, surgical excision, radiation therapy, and intradermal chemotherapy (e.g. vinblastine) can be used to treat the symptoms. These local therapies do not prevent new KS lesions from developing. For more severe and aggressive KS, systemic chemotherapy with agents such as liposomal anthracyclines (doxorubicin and daunorubicin; first-line) and paclitaxel (second-line) is usually the mainstay of treatment. Other chemotherapeutics include vinorelbine, interferon-α, and interleukin-12. Although
Note: Due to the space restriction, only KSHV unique genes marked with an asterisk were discussed in more detail in the text.

### Table 2
Unique ORFs encoded by KSHV.

<table>
<thead>
<tr>
<th>ORF</th>
<th>Alternative name</th>
<th>Functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>K1'</td>
<td>VIP</td>
<td>Transformation; B cell activation; inhibition of apoptosis; downregulation of surface B cell receptor (BCR); and activation of PI3 K/ Akt/mTOR kinases</td>
</tr>
<tr>
<td>K2'</td>
<td>vIL-6</td>
<td>IL-6 homolog; B cell proliferation; and autocrine/paracrine signaling</td>
</tr>
<tr>
<td>K3</td>
<td>MIR1</td>
<td>E3 ubiquitin ligase; immune evasion; and inhibition of MHC class I and T cell killing</td>
</tr>
<tr>
<td>K4</td>
<td>vMIP-II; vMIP-1b; and vCCL-2</td>
<td>MIP-I homolog; angiogenesis; CCR3 and CCR8 binding; and chemotactraction of TH2 cells and monocytes (immune modulation)</td>
</tr>
<tr>
<td>K4.1</td>
<td>vMIP-III; vBCK; and vCCL3</td>
<td>TARC/etoxin homolog; induction of VEGF-A and angiogenesis; CCR4 binding; chemotactraction of TH2 cells (immune modulation)</td>
</tr>
<tr>
<td>K5</td>
<td>MIK2</td>
<td>E3 ubiquitin ligase; immune evasion; and inhibition of MHC class I, B7, and ICAM expression</td>
</tr>
<tr>
<td>K6</td>
<td>vMIP-I; vMIP-1a; and vCCL-1</td>
<td>MIP-I homolog; angiogenesis; CCR5 and CCR8 binding; and chemotactraction of TH2 cells and monocytes</td>
</tr>
<tr>
<td>K7</td>
<td>Survivin and vIAP</td>
<td>Inhibitor of apoptosis protein (IAP) homolog and inhibition of vGPCR expression and function</td>
</tr>
<tr>
<td>K8</td>
<td>K-bZIP</td>
<td>An immediate-early gene that represses Rta transactivation activity and Rta induction of KSHV lytic cycle</td>
</tr>
<tr>
<td>K8.1</td>
<td>vIRF-1</td>
<td>Viral glycoprotein (structural protein)</td>
</tr>
<tr>
<td>K9</td>
<td>vIRF-4</td>
<td>IRF homolog; Inhibition of type I interferon, p300, p53, and TGF-β; and transformation</td>
</tr>
<tr>
<td>K10</td>
<td>vIRF-2 (K11.5)</td>
<td>IRF homolog; inhibition of type I interferon production and apoptosis (PKR- and caspase-3 mediated); inhibition of p53 and NFkB; and inhibition of fas-mediated apoptosis via inhibition of CD95L surface expression</td>
</tr>
<tr>
<td>K11, K11.1, and K11.5</td>
<td>vIRF-2 (K11.5)</td>
<td>IRF homolog; inhibition of type I interferon and NFkB and inhibition of Fas-mediated apoptosis via inhibition of CD95L surface expression</td>
</tr>
<tr>
<td>K12</td>
<td>Kaposin</td>
<td>Transformation (Kaposin A) and cytokine and AU-rich mRNA stabilization by induction of p38 and MK2 signaling (Kaposin B)</td>
</tr>
<tr>
<td>K13</td>
<td>vFLIP</td>
<td>FLIP homolog; transactivator of NFkB; anti-apoptotic function; and transformation</td>
</tr>
<tr>
<td>K14</td>
<td>vOx-2</td>
<td>Ox-2 (CD200) homolog; downregulation of myeloid cell activation; and regulation of inflammatory cytokine production such as IL-1β, TNF-α, IL-8, IFN-γ, and IL-6</td>
</tr>
<tr>
<td>K15</td>
<td>LAMP</td>
<td>Activation of the intracellular signaling pathways (Ras/MAPK, NFkB, and JNK/SAPK), leading to IL-6, IL-8, and Cox-2 induction. A chimeric protein consisting of the CD8 extracellular domain of CD8 and the K15 cytoplasmic domain could inhibit BCR signaling</td>
</tr>
</tbody>
</table>

The approaches mentioned above have some beneficial effects to the patients, they are not very effective, as they do not target specifically the agent causing the tumor. The mTOR inhibitor, rapamycin (Sirolimus) was tested against iatrogenic KS and was highly successful [149,150]. In AIDS-KS patients, HAART is recommended to reduce the extent and size of KS lesions. HAART might also reduce the incidence of new KS in HIV-positive individuals. These beneficial effects are likely due to immune reconstitution. In addition to HAART, the tyrosine kinase inhibitor imatinib, and IL-12 also demonstrate some activities against AIDS-KS [151,152].

PEL patients have very poor prognosis and have a median survival of only 2–3 months after diagnosis. As in the case of KS, a patient co-infected with HIV is likely to benefit from HAART [153]. Complete remission of PEL with HAART is seen occasionally [153–155]. On the other hand, conventional CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone) did not improve survival compared to other HIV-associated NHL [154]. For HIV-negative cases of PEL, patients may be given liposomal anthracycline with or without bortezomib (proteasome inhibitor) and prednisone. Bortezomib was reported to be efficacious in treating PEL cell lines when it was used alone or in combination with doxorubicin and Taxol [156]. Rapamycin has also shown promise in treating PEL cells in culture and in a xenograft model [157]. Although radiation therapy is rarely performed to treat PEL, it may be an option for patients who do not tolerate the above treatment options.

Treatment options for MCD include surgical excision, cytoreductive chemotherapy (CHOP or CVAD), radiation therapy, immune modulators such as steroids and interferon-α, thalidomide, monoclonal antibodies against IL-6 (atildimab) and CD20 surface marker (rituximab), and inhibitors of KSHV viral replication (reviewed in [32,158]). The patient responses to these therapeutic options are mixed and therefore, the establishment of treatment regimens requires more epidemiological data. As a general rule of thumb, chemotherapy is preferred for MCD with severe systemic symptoms; the viral replication inhibitors (especially ganciclovir), interferon-α, and anti-IL-6 and anti-CD20 monoclonal antibodies appear to be the more specific and promising candidates for treating MCD [158].

In conclusion, the current treatment strategies for KS, PEL, and MCD are still sub-optimal. While our understanding of KSHV biology and tumorigenesis has been increasing since the discovery of the virus, we are just beginning to translate knowledge from basic science research into more effective clinical management and therapies. We believe that the use of antiviral agents and small molecules that specifically target the signaling pathways of these tumor cells are potentially more efficacious and have fewer side effects than conventional chemotherapy regimens. More case reports and randomized clinical trials are needed to advance and standardize treatments for KSHV-associated malignancies.

Conflict of interest

The authors have no conflict of interest to disclose.

Acknowledgements

Due to space restrictions we regret that we had to omit many important references. KWW is supported in part by NIAID training grant T32-AI007001 and MSTP Grant T32-GM008719. BD is a Leukemia and Lymphoma Society Scholar and a Burroughs Welcome Fund Investigator in Infectious Disease. Her work is supported by Grants CA096500, DE18281, and HL083469 from the NIH.

References


To analyze the possible consequences of these findings, we examined the expression of v-chk1 protein levels in KSHV-positive cells using immunoblotting. The results showed that the level of v-chk1 protein expression was significantly higher in KSHV-infected cells than in uninfected controls.

In conclusion, our study provides evidence for the involvement of v-chk1 protein in Kaposi’s sarcoma pathogenesis. Our findings suggest that inhibition of v-chk1 protein expression may be a potential therapeutic target for the treatment of Kaposi’s sarcoma. Further studies are needed to explore the role of v-chk1 protein in the development of Kaposi’s sarcoma and to develop effective therapeutic strategies for this disease.